SEC Comment Letter for BIOSPECIFICS TECHNOLOGIES CORP (CIK 0000875622) — Jun 30, 2020
BIOSPECIFICS TECHNOLOGIES CORP (CIK 0000875622)
Date: June 30, 2020 · CIK: 0000875622 · Accession: 0000000000-20-005884
AI Filing Summary & Sentiment
File numbers found in text: 333-239484
Letter
United States securities and exchange commission logo June 30, 2020 Joseph Truitt Chief Executive Officer BioSpecifics Technologies Corp. 2 Righter Parkway, Suite 200 Wilmington, DE 19803 Re:BioSpecifics Technologies Corp. Registration Statement on Form S-3 Filed June 26, 2020 File No. 333-239484 Dear Mr. Truitt: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Celia A. Soehner, Esq.
Show Raw Text
United States securities and exchange commission logo
June 30, 2020
Joseph Truitt
Chief Executive Officer
BioSpecifics Technologies Corp.
2 Righter Parkway, Suite 200
Wilmington, DE 19803
Re:BioSpecifics Technologies Corp.
Registration Statement on Form S-3
Filed June 26, 2020
File No. 333-239484
Dear Mr. Truitt:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Celia A. Soehner, Esq.